William Perry, MD
Family Medicine · Centre, ALNPI 1538184635
Payments from drug & device makers
Across 284 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$611
- Boehringer Ingelheim$476
- AbbVie$406
- AstraZeneca$326
- Pfizer$295
- Lilly USA, LLC$284
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,479100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $611 |
| Boehringer Ingelheim | 33 | $476 |
| AbbVie(2 entities) | 27 | $406 |
| AstraZeneca | 19 | $326 |
| Pfizer | 19 | $295 |
| Lilly USA, LLC | 19 | $284 |
| Otsuka America Pharmaceutical, Inc. | 10 | $227 |
| Bayer | 13 | $208 |
| Merck | 11 | $191 |
| Novartis | 12 | $176 |
| Astellas Pharma US Inc | 6 | $151 |
| Amgen | 8 | $130 |
| Dexcom, Inc. | 7 | $115 |
| Johnson & Johnson | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $93 |
| Novo Nordisk | 5 | $70 |
| E.r. Squibb & Sons, L.L.C. | 5 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Exact Sciences | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Antares Pharma, Inc. | 2 | $37 |
| Genentech USA, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Vertex | 1 | $18 |
| Tolmar, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$4,479 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $137,722 |
| OzempicSemaglutide | 75 | $89,534 |
| MounjaroTirzepatide | 69 | $79,286 |
| XareltoRivaroxaban | 80 | $73,579 |
| JanuviaSitagliptin Phosphate | 55 | $52,218 |
| TrulicityDulaglutide | 43 | $46,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $43,683 |
| JardianceEmpagliflozin | 57 | $34,390 |
| EntrestoSacubitril/Valsartan | 44 | $32,091 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $27,617 |
| FarxigaDapagliflozin Propanediol | 22 | $17,754 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $17,107 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $11,433 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $10,685 |
| LinzessLinaclotide | 18 | $8,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $295 | $144,678221 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $125,665112 claims |
| Novo NordiskOzempic | $70 | $89,53475 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arexvy | $611 | $81,294134 claims |
| Johnson & JohnsonXarelto | $98 | $73,57980 claims |
| MerckJanuvia, Janumet, Belsomra | $191 | $69,27791 claims |
| Boehringer IngelheimJardiance | $476 | $34,39057 claims |
| NovartisEntresto | $176 | $32,09144 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $326 | $26,44436 claims |
| AbbVieLinzess | $406 | $8,76418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Centre
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.